Applications of N-Boc-N'-Xanthyl-L-Asparagine in Industrial Manufacturing

As a direct producer of N-Boc-N'-Xanthyl-L-Asparagine, our technical team ensures rigorous quality control for integration across advanced industrial sectors. Below we detail specific downstream manufacturing uses, highlighting real process parameters observed in ongoing B2B supply relationships.

1. Peptide Synthesis for Specialty Active Pharmaceutical Ingredient Production

Pharmaceutical manufacturers deploy this protected asparagine analogue in the stepwise construction of complex peptides, particularly when selective deprotection or post-assembly modification is necessary. The xanthyl and Boc groups enhance orthogonality in solid phase synthesis, aiding sequence control. Our material aligns with production runs of high-value APIs, including candidates for next-gen peptide drugs where functional group selectivity is essential to achieving high sequence purity and minimized byproduct formation.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• European Pharmacopoeia (Ph. Eur.) monographs for peptide intermediates
• USP General Chapter <795> for non-sterile pharmaceutical compounding
• EMA Guidelines on Peptide API Manufacturing (EMA/CHMP/ICH/3706/99)

Typical usage ratio

• Coupling reactions: 0.8–1.1 eq per peptide elongation cycle, adjusted based on resin loading and coupling efficiency

Downstream process integration

• Pre-activated in on-resin peptide assembly following Fmoc deprotection cycles and prior to next amino acid coupling

Final product types

• Peptide pharmaceutical intermediates
• Custom therapeutic peptide APIs
• Diagnostic peptide markers
• Investigational oncologic peptide candidates

2. Protected Amino Acid Supply for Advanced Oligonucleotide-Peptide Conjugate Development

Oligonucleotide therapeutic manufacturers use this derivative to introduce asparagine residues in hybrid biomolecule chains, particularly when assembling oligonucleotide–peptide conjugates via solid-phase routes. The xanthyl function offers selective reactivity for downstream conjugation and branching, aiding the synthesis of multi-modal therapeutics with improved pharmacokinetic properties for clinical use.

Industry compliance standards

• FDA Guidance for Industry: CGMP for Oligonucleotide Therapeutics
• USP <1045> Biotechnology-derived Articles
• ISO 9001:2015 Quality Management for Life Sciences
• OECD Principles of Good Laboratory Practice (GLP)

Typical usage ratio

• 0.9–1.2 molar equivalents per asparagine coupling step; ratio varies by target sequence length and functionalization pattern

Downstream process integration

• Introduced during SPPS cycles on mixed oligonucleotide–peptide resins at specific branching points or linker introduction

Final product types

• Antisense oligonucleotide–peptide conjugates
• Peptide nucleic acid (PNA) hybrids
• siRNA delivery agents
• Bioconjugated research tools

3. Chemical Synthesis of Site-specific Labeling Reagents for Proteomics

Proteomic workflow solution providers utilize our material as a building block for developing cleavable or photoreactive labeling agents targeting asparagine residues on proteins. The Boc/xanthyl pattern allows for precise downstream cleavage and site-selective modification in proteome mapping and mass spectrometry protocols. Industrial labs often select this material for scalable, reproducible synthesis when producing labeling reagents for large-volume proteomics utilities.

Industry compliance standards

• Nature Methods chemical labeling protocols
• ISO/IEC 17025 for testing and calibration laboratories
• EN ISO 13485 for development of in vitro diagnostic reagents
• GLP (Good Laboratory Practice) per OECD requirements

Typical usage ratio

• Conversion to active labeling reagent: 0.7–1.3 eq, depending on scale and target protein abundance

Downstream process integration

• Converted into labeling moiety, then applied post-protein digestion for site-specific residue targeting in automated instrument workflows

Final product types

• MS-cleavable protein labeling kits
• Reagents for site-directed mutagenesis studies
• Tagged proteomic standard peptides
• Photo-activated cross-linkers

4. Synthesis of Modified Polypeptide Scaffolds for Advanced Biomaterials

Biomaterial manufacturers incorporate this functionalized asparagine building block in the synthesis of modified polypeptide scaffolds used for hydrogel matrices, tissue engineering, and surface modification applications. The dual protection handles enable controlled deprotection and functionalization steps, facilitating uniform scaffold chemistry vital for biocompatibility and downstream reactivity in medical and research settings.

Industry compliance standards

• ISO 10993 for biological evaluation of medical devices
• FDA 21 CFR 820 Quality System Regulation for medical device components
• USP <1031> The Biocompatibility of Materials Used in Drug Containers, Medical Devices, and Implants
• ASTM F2027 – Standard Guide for Characterization of Polymer Blends and Alloys

Typical usage ratio

• 0.5–2.0 mol% of total amino acid input, adjusted by desired scaffold functionalization and downstream cross-linking needs

Downstream process integration

• Introduced during step-growth polymerization for side-chain modification prior to hydrogel or film casting

Final product types

• Injectable polypeptide hydrogels
• Biocompatible surface coatings
• Tissue scaffold implants
• Cell culture substrates for regenerative medicine